Personalized
Precision Care

Dynamic Disease Management of
Autoimmune & Inflammatory Diseases

Using RNA Analytics and Predictive AI

AMPEL Genomic Platform (AGP®) supports
genomic blood and biopsy tests for patients:

Evaluate disease status

Identify cells, functions and pathways

Predict flares and drug targets

Key Stats

 

95%
coverage of all known genes and is disease agnostic

25,000+
autoimmune and normal patient gene expression profiles with rich clinical information – world’s largest for Lupus

50+
technology patents filed & pending with the freedom to operate

20+
pharma customers validate the technology

5+
additional autoimmunity products in development

Featured News

About the Founders

AMPEL’s co-founders, Amrie Grammer and Peter Lipsky, are internationally recognized scientists and successful entrepreneurs. Their success has been a combination of world-class science with business acumen. In 2023, AMPEL was recognized as Virginia’s Innovator-of-the-Year by CBIC.  Last year, the Coalition of 21st Century Precision Medicine elected AMPEL to membership.  Earlier this year, AMPEL was ranked by Nature in the top Precision Medicine Companies with respect to the impact of published science (Foundation Medicine, Illumina, Tempus, ThermoFischer, AMPEL BioSolutions, Guardant Health, AdaptiveTechnologies) and received a Virginia Catalyst Award

Personalized
Precision Medicine

Powered by research and analytics, we use genomic data to reduce uncertainty from clinical care.

Pin It on Pinterest